Astrazeneca Pharma India Ltd Competitors & Peer Comparison
Pharmaceuticals · Indian listed companies
Compare Astrazeneca Pharma India Ltd with 125 companies shown from the same industry classification, including Marksans Pharma Ltd, Concord Biotech Ltd, Jubilant Pharmova Ltd. These are industry peers; their products, customers and business models may differ.
Selected-company price and ratio data: . Peer reporting dates can differ. Stored figures, not live quotes.
Compare valuation, size and returns
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Pharma India Ltd | 14,941 Cr. | 5,980 | 9,850/5,882 | 86.1 | 349 | 0.60 % | 29.3 % | 23.3 % | 2.00 |
| Marksans Pharma Ltd | 14,707 Cr. | 324 | 351/155 | 28.5 | 66.7 | 0.28 % | 18.8 % | 15.2 % | 1.00 |
| Concord Biotech Ltd | 14,175 Cr. | 1,356 | 1,648/987 | 49.8 | 193 | 0.56 % | 17.4 % | 12.6 % | 1.00 |
| Jubilant Pharmova Ltd | 15,776 Cr. | 989 | 1,185/784 | 40.6 | 445 | 0.51 % | 8.99 % | 6.53 % | 1.00 |
| Natco Pharma Ltd | 16,145 Cr. | 824 | 1,217/786 | 14.1 | 470 | 0.61 % | 17.4 % | 17.1 % | 2.00 |
| Alembic Pharmaceuticals Ltd | 16,399 Cr. | 834 | 998/635 | 22.0 | 289 | 1.44 % | 12.6 % | 13.4 % | 2.00 |
| ERIS Lifesciences Ltd | 16,459 Cr. | 1,185 | 1,740/1,163 | 25.1 | 282 | 0.61 % | 14.1 % | 18.7 % | 1.00 |
| Cohance Lifesciences Ltd | 17,487 Cr. | 457 | 918/267 | 162 | 102 | 0.00 % | 5.81 % | 4.89 % | 1.00 |
| Pfizer Ltd | 17,633 Cr. | 3,852 | 5,578/3,792 | 22.9 | 919 | 1.95 % | 24.1 % | 18.0 % | 10.0 |
| Blue Jet Healthcare Ltd | 10,198 Cr. | 538 | 693/325 | 43.4 | 78.4 | 0.22 % | 26.1 % | 19.4 % | 2.00 |
| Caplin Point Laboratories Ltd | 20,372 Cr. | 2,680 | 2,991/1,500 | 30.6 | 443 | 0.30 % | 24.2 % | 20.9 % | 2.00 |
| Shilpa Medicare Ltd | 21,008 Cr. | 1,074 | 1,096/260 | 73.9 | 132 | 0.06 % | 10.9 % | 8.99 % | 1.00 |
| Aarti Pharmalabs Ltd | 8,838 Cr. | 975 | 1,002/584 | 41.0 | 234 | 0.36 % | 10.7 % | 8.59 % | 5.00 |
| Procter & Gamble Health Ltd | 8,805 Cr. | 5,306 | 6,975/4,700 | 26.4 | 316 | 2.92 % | 83.9 % | 61.9 % | 10.0 |
| Sequent Scientific Ltd | 8,768 Cr. | 201 | 260/111 | 203 | 32.2 | 0.00 % | 8.47 % | 3.21 % | 2.00 |
| Suven Life Sciences Ltd | 8,741 Cr. | 309 | 403/124 | 22.4 | 0.00 % | 79.5 % | 81.5 % | 1.00 | |
| Morepen Laboratories Ltd | 7,888 Cr. | 144 | 145/33.0 | 67.2 | 22.8 | 0.14 % | 8.05 % | 5.33 % | 2.00 |
| Entero Healthcare Solutions Ltd | 7,378 Cr. | 1,697 | 1,920/944 | 57.2 | 388 | 0.00 % | 10.5 % | 6.94 % | 10.0 |
| Bliss GVS Pharma Ltd | 7,240 Cr. | 676 | 745/118 | 52.6 | 113 | 0.22 % | 16.9 % | 11.8 % | 1.00 |
| Granules India Ltd | 22,831 Cr. | 836 | 924/520 | 35.1 | 205 | 0.21 % | 15.5 % | 13.8 % | 1.00 |
| Sanofi India Ltd | 7,015 Cr. | 3,047 | 4,898/3,000 | 20.5 | 359 | 2.46 % | 57.5 % | 43.0 % | 10.0 |
| IOL Chemicals & Pharmaceuticals Ltd | 6,311 Cr. | 215 | 219/67.1 | 35.7 | 61.3 | 0.47 % | 11.3 % | 8.42 % | 2.00 |
| Orchid Pharma Ltd | 6,022 Cr. | 1,007 | 1,144/471 | 333 | 300 | 0.00 % | 1.86 % | 1.49 % | 10.0 |
| FDC Ltd | 5,426 Cr. | 334 | 474/313 | 17.6 | 153 | 1.50 % | 15.4 % | 11.2 % | 1.00 |
| RPG Life Sciences Ltd | 4,858 Cr. | 2,933 | 3,130/1,731 | 41.6 | 366 | 0.82 % | 25.7 % | 19.3 % | 8.00 |
| Gujarat Themis Biosyn Ltd | 4,855 Cr. | 374 | 479/225 | 99.7 | 26.4 | 0.18 % | 18.1 % | 17.4 % | 1.00 |
| SMS Pharmaceuticals Ltd | 4,428 Cr. | 472 | 494/262 | 48.9 | 85.9 | 0.08 % | 12.9 % | 11.9 % | 1.00 |
| Zota Health Care Ltd | 4,428 Cr. | 1,279 | 1,740/1,022 | 200 | 0.08 % | 8.47 % | 15.0 % | 10.0 | |
| Gufic BioSciences Ltd | 4,281 Cr. | 428 | 468/268 | 58.2 | 66.2 | 0.02 % | 12.2 % | 9.98 % | 1.00 |
| Acutaas Chemicals Ltd | 25,873 Cr. | 3,157 | 3,740/1,375 | 67.0 | 202 | 0.08 % | 31.6 % | 24.0 % | 5.00 |
| Aarti Drugs Limited | 3,912 Cr. | 429 | 534/319 | 22.6 | 154 | 0.47 % | 11.7 % | 12.7 % | 10.0 |
| Kwality Pharmaceuticals Ltd | 3,889 Cr. | 3,745 | 3,949/829 | 47.6 | 321 | 0.00 % | 23.9 % | 22.5 % | 10.0 |
| Unichem Laboratories Ltd | 3,857 Cr. | 548 | 687/278 | 31.6 | 386 | 0.00 % | 4.13 % | 3.17 % | 2.00 |
| Ind-Swift Laboratories Ltd | 3,499 Cr. | 400 | 425/87.0 | 53.8 | 159 | 0.00 % | 4.86 % | 4.02 % | 10.0 |
| Solara Active Pharma Sciences Ltd | 3,315 Cr. | 683 | 774/422 | 776 | 346 | 0.00 % | 4.86 % | 0.13 % | 10.0 |
| Advanced Enzyme Technologies Ltd | 3,054 Cr. | 273 | 420/252 | 19.4 | 146 | 1.96 % | 14.0 % | 10.2 % | 2.00 |
| Hikal Ltd | 2,792 Cr. | 226 | 261/146 | 65.8 | 97.2 | 0.26 % | 3.50 % | 2.21 % | 2.00 |
| Dishman Carbogen Amcis Ltd | 2,413 Cr. | 154 | 307/128 | 133 | 426 | 0.00 % | 3.14 % | 1.58 % | 2.00 |
| Venus Remedies Ltd | 2,370 Cr. | 1,747 | 2,044/432 | 20.4 | 497 | 0.57 % | 20.7 % | 15.6 % | 10.0 |
| Indoco Remedies Ltd | 2,279 Cr. | 247 | 317/162 | 102 | 0.08 % | 0.96 % | 9.36 % | 2.00 | |
| Fredun Pharmaceuticals Ltd | 2,258 Cr. | 1,363 | 1,600/454 | 50.8 | 170 | 0.02 % | 21.5 % | 15.8 % | 10.0 |
| Panacea Biotec Ltd | 2,230 Cr. | 363 | 648/292 | 136 | 0.00 % | 2.43 % | 2.42 % | 1.00 | |
| Beta Drugs Ltd | 2,219 Cr. | 2,001 | 2,808/990 | 48.7 | 241 | 0.00 % | 19.2 % | 18.8 % | 10.0 |
| Syncom Formulations (India) Ltd | 2,185 Cr. | 23.2 | 27.5/10.2 | 25.7 | 4.39 | 0.43 % | 24.8 % | 17.6 % | 1.00 |
| Hester Biosciences Ltd | 1,849 Cr. | 2,174 | 2,684/1,239 | 34.8 | 423 | 0.51 % | 15.2 % | 15.9 % | 10.0 |
| Neuland Laboratories Ltd | 28,127 Cr. | 21,905 | 24,235/11,500 | 56.5 | 1,461 | 0.16 % | 26.5 % | 21.2 % | 10.0 |
| Fermenta Biotech Ltd | 1,646 Cr. | 557 | 580/249 | 30.1 | 138 | 0.67 % | 20.6 % | 16.4 % | 5.00 |
| Jagsonpal Pharmaceuticals Ltd | 1,541 Cr. | 234 | 265/155 | 32.8 | 41.2 | 1.71 % | 22.7 % | 17.3 % | 2.00 |
| Amrutanjan Health Care Ltd | 1,517 Cr. | 524 | 760/476 | 24.4 | 128 | 0.94 % | 24.8 % | 18.4 % | 1.00 |
| TTK Healthcare Ltd | 1,458 Cr. | 1,034 | 1,250/735 | 19.0 | 789 | 0.97 % | 8.04 % | 6.30 % | 10.0 |
| Kopran Ltd | 1,303 Cr. | 270 | 296/107 | 52.1 | 110 | 1.11 % | 6.65 % | 4.91 % | 10.0 |
| Lincoln Pharmaceuticals Ltd | 1,155 Cr. | 578 | 770/440 | 12.0 | 378 | 0.31 % | 16.3 % | 12.3 % | 10.0 |
| Themis Medicare Ltd | 1,052 Cr. | 113 | 147/65.0 | 43.3 | 0.44 % | 2.74 % | 0.41 % | 1.00 | |
| Bafna Pharmaceuticals Ltd | 917 Cr. | 394 | 401/94.8 | 118 | 40.6 | 0.00 % | 11.9 % | 12.3 % | 10.0 |
| Kilitch Drugs (India) Ltd | 912 Cr. | 261 | 268/117 | 30.4 | 80.0 | 0.00 % | 13.4 % | 10.6 % | 10.0 |
| Anuh Pharma Ltd | 878 Cr. | 87.6 | 99.5/66.7 | 19.9 | 35.1 | 1.71 % | 14.9 % | 10.7 % | 5.00 |
| Wanbury Ltd | 696 Cr. | 198 | 360/162 | 16.2 | 18.1 | 0.00 % | 36.6 % | 76.5 % | 10.0 |
| Albert David Ltd | 480 Cr. | 839 | 932/580 | 21.3 | 686 | 0.60 % | 0.82 % | 0.44 % | 10.0 |
| SMS Lifesciences India Ltd | 357 Cr. | 1,197 | 1,680/956 | 20.6 | 650 | 0.13 % | 11.8 % | 10.8 % | 10.0 |
| Aarey Drugs & Pharmaceuticals Ltd | 346 Cr. | 108 | 109/50.3 | 83.1 | 53.0 | 0.00 % | 5.58 % | 2.75 % | 10.0 |
| BDH Industries Ltd | 283 Cr. | 491 | 610/340 | 24.2 | 134 | 1.02 % | 20.5 % | 14.8 % | 10.0 |
| Lyka Labs Ltd | 269 Cr. | 75.3 | 105/44.1 | 25.9 | 0.00 % | 5.98 % | 10.2 % | 10.0 | |
| Gennex Laboratories Ltd | 241 Cr. | 9.90 | 17.2/7.05 | 12.8 | 9.16 | 0.00 % | 11.8 % | 10.5 % | 1.00 |
| Everest Organics Ltd | 235 Cr. | 236 | 536/197 | 44.8 | 77.7 | 0.00 % | 12.0 % | 7.63 % | 10.0 |
| Nectar Lifescience Ltd | 211 Cr. | 11.0 | 22.5/9.20 | 30.0 | 0.00 % | 0.05 % | 31.3 % | 1.00 | |
| Ambalal Sarabhai Enterprises Ltd | 203 Cr. | 26.5 | 42.0/23.1 | 11.4 | 19.2 | 0.00 % | 9.12 % | 6.25 % | 10.0 |
| Coral Laboratories Ltd | 201 Cr. | 562 | 679/360 | 10.6 | 585 | 0.36 % | 11.0 % | 7.79 % | 10.0 |
| Brooks Laboratories Ltd | 174 Cr. | 59.7 | 132/36.3 | 13.2 | 41.6 | 0.00 % | 21.2 % | 22.0 % | 10.0 |
| Bal Pharma Ltd | 160 Cr. | 101 | 125/59.7 | 22.3 | 51.6 | 1.18 % | 9.75 % | 7.79 % | 10.0 |
| Par Drugs & Chemicals Ltd | 151 Cr. | 123 | 180/78.0 | 10.4 | 91.0 | 0.00 % | 14.6 % | 9.95 % | 10.0 |
| Auro Laboratories Ltd | 142 Cr. | 228 | 317/159 | 29.6 | 74.4 | 0.00 % | 9.52 % | 8.49 % | 10.0 |
| Achyut Healthcare Ltd | 137 Cr. | 5.66 | 10.0/4.70 | 427 | 1.45 | 0.00 % | 1.18 % | 0.96 % | 1.00 |
| Lactose (India) Ltd | 135 Cr. | 107 | 136/76.0 | 19.4 | 51.5 | 0.00 % | 11.3 % | 9.81 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 133 Cr. | 9.09 | 14.3/1.96 | 44.4 | 0.81 | 0.00 % | 22.9 % | 16.6 % | 1.00 |
| Godavari Drugs Ltd | 127 Cr. | 117 | 135/69.7 | 32.7 | 74.8 | 0.00 % | 6.55 % | 6.14 % | 10.0 |
| Krebs Biochemicals & Industries Ltd | 127 Cr. | 58.9 | 76.8/38.3 | 75.5 | 0.00 % | 15.4 % | % | 10.0 | |
| Alpa Laboratories Ltd | 123 Cr. | 58.7 | 99.8/46.0 | 28.2 | 93.4 | 0.00 % | 8.91 % | 7.90 % | 10.0 |
| Vaishali Pharma Ltd | 107 Cr. | 8.17 | 11.6/4.75 | 25.1 | 5.29 | 0.00 % | 8.93 % | 6.02 % | 2.00 |
| Pharmaids Pharmaceuticals Ltd | 107 Cr. | 30.2 | 60.0/25.6 | 13.5 | 0.00 % | 18.5 % | 26.5 % | 10.0 | |
| Concord Drugs Ltd | 101 Cr. | 76.9 | 92.5/61.0 | 49.7 | 36.8 | 0.00 % | 5.19 % | 2.52 % | 10.0 |
| Denis Chem Lab Ltd | 93.3 Cr. | 67.3 | 97.4/56.1 | 11.7 | 66.0 | 3.72 % | 14.0 % | 9.52 % | 10.0 |
| Ind-Swift Ltd | 85.4 Cr. | 15.8 | / | 10.9 | 74.2 | 0.00 % | 11.9 % | % | 2.00 |
| Fervent Synergies Ltd | 77.0 Cr. | 15.4 | 26.0/13.0 | 21.2 | 11.4 | 0.00 % | 7.21 % | 7.22 % | 10.0 |
| Cian Healthcare Ltd | 62.4 Cr. | 25.0 | 25.0/4.72 | 3.42 | 0.00 % | 15.1 % | 49.2 % | 10.0 | |
| Vivimed Labs Ltd | 53.0 Cr. | 6.28 | 29.4/4.75 | 25.4 | 0.00 % | 65.2 % | % | 2.00 | |
| ANG Lifesciences India Ltd | 50.4 Cr. | 38.6 | 49.7/17.6 | 47.6 | 0.00 % | 1.14 % | 7.38 % | 10.0 | |
| Mangalam Drugs and Organics Ltd | 49.3 Cr. | 31.9 | 74.0/22.7 | 65.3 | 0.00 % | 14.0 % | 34.8 % | 10.0 | |
| Biofil Chemicals & Pharmaceuticals Ltd | 49.1 Cr. | 30.1 | 46.8/25.6 | 102 | 13.2 | 0.00 % | 2.97 % | 2.83 % | 10.0 |
| Murae Organisor Ltd | 38.8 Cr. | 0.19 | 0.53/0.19 | 2.56 | 1.02 | 0.00 % | 4.20 % | 5.69 % | 1.00 |
| Bacil Pharma Ltd | 38.4 Cr. | 26.8 | 61.8/10.6 | 59.1 | 17.3 | 0.00 % | 3.93 % | 6.21 % | 10.0 |
| Bharat Immunological & Biological Corporation Ltd | 35.8 Cr. | 8.28 | 22.6/7.11 | 18.2 | 0.00 % | 9.27 % | 17.7 % | 10.0 | |
| Chandra Bhagat Pharma Ltd | 35.4 Cr. | 46.9 | 53.0/29.7 | 11.6 | 43.9 | 0.00 % | 12.1 % | 9.67 % | 10.0 |
| Gujarat Terce Laboratories Ltd | 27.1 Cr. | 34.8 | 59.8/29.0 | 12.2 | 12.5 | 0.00 % | 39.2 % | 30.2 % | 10.0 |
| Colinz Laboratories Ltd | 18.4 Cr. | 73.0 | 87.9/36.1 | 36.8 | 39.9 | 0.00 % | 7.20 % | 5.23 % | 10.0 |
| Checkpoint Trends Ltd | 18.0 Cr. | 32.8 | 144/28.4 | 14.6 | 42.5 | 0.00 % | 15.0 % | 12.7 % | 10.0 |
| Ortin Laboratories Ltd | 16.4 Cr. | 20.1 | 26.4/16.2 | 3.47 | 0.00 % | 60.2 % | 118 % | 10.0 | |
| Desh Rakshak Aushdhalaya Ltd | 15.3 Cr. | 26.9 | 59.6/22.4 | 27.9 | 23.3 | 0.00 % | 7.50 % | 5.59 % | 10.0 |
| Beryl Drugs Ltd | 13.1 Cr. | 25.9 | 27.6/15.9 | 21.2 | 19.5 | 0.00 % | 7.25 % | 4.34 % | 10.0 |
| Chemo Pharma Laboratories Ltd | 11.4 Cr. | 75.9 | 153/70.0 | 8.60 | 0.00 % | 0.28 % | 0.28 % | 10.0 | |
| Dipna Pharmachem Ltd | 11.2 Cr. | 4.28 | 25.0/3.90 | 4.28 | 23.7 | 0.00 % | 7.64 % | 5.22 % | 10.0 |
| Adline Chem Lab Ltd | 9.24 Cr. | 15.8 | 16.2/7.60 | 3.03 | 0.00 % | 1,267 % | % | 10.0 | |
| Ganga Pharmaceuticals Ltd | 7.39 Cr. | 12.5 | 14.0/9.35 | 73.9 | 14.1 | 0.00 % | 2.90 % | 1.30 % | 10.0 |
| Brawn Biotech Ltd | 7.35 Cr. | 24.5 | 24.7/17.7 | 8.65 | 14.5 | 0.00 % | 0.00 % | 24.4 % | 10.0 |
| Decipher Labs Ltd | 5.73 Cr. | 5.67 | 11.0/5.00 | 20.5 | 0.00 % | 16.7 % | 14.2 % | 10.0 | |
| Amerise Biosciences Ltd | 5.42 Cr. | 0.82 | 1.03/0.50 | 0.82 | 0.00 % | 0.37 % | 0.37 % | 1.00 | |
| Fabino Enterprises Ltd | 4.27 Cr. | 20.3 | 27.0/13.0 | 18.7 | 0.00 % | 6.22 % | 8.76 % | 10.0 | |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 2.08/1.57 | 0.04 | 0.00 % | 13.1 % | 177 % | 10.0 | |
| Evoq Remedies Ltd | 3.78 Cr. | 1.52 | 6.11/1.35 | 17.8 | 0.00 % | 0.56 % | 0.54 % | 10.0 | |
| Wockhardt Ltd | 35,397 Cr. | 2,176 | 2,422/1,087 | 88.8 | 304 | 0.00 % | 7.55 % | 6.11 % | 5.00 |
| J B Chemicals & Pharmaceuticals Ltd | 38,677 Cr. | 2,409 | 2,526/1,642 | 53.8 | 259 | 0.91 % | 25.4 % | 18.9 % | 1.00 |
| Ajanta Pharma Ltd | 44,622 Cr. | 3,573 | 3,797/2,380 | 39.3 | 362 | 0.90 % | 34.5 % | 27.1 % | 2.00 |
| Glaxosmithkline Pharmaceuticals Ltd | 46,647 Cr. | 2,755 | 3,121/2,088 | 44.3 | 134 | 2.07 % | 61.4 % | 45.6 % | 10.0 |
| Ipca Laboratories Ltd | 49,357 Cr. | 1,946 | 2,039/1,252 | 35.9 | 318 | 0.31 % | 17.0 % | 15.7 % | 1.00 |
| Gland Pharma Ltd | 49,578 Cr. | 3,006 | 3,042/1,574 | 35.1 | 656 | 0.67 % | 17.4 % | 12.8 % | 1.00 |
| Abbott India Ltd | 55,346 Cr. | 26,115 | 30,655/25,135 | 34.3 | 2,247 | 2.01 % | 44.8 % | 34.4 % | 10.0 |
| Biocon Ltd | 60,160 Cr. | 369 | 447/338 | 82.7 | 210 | 0.14 % | 3.61 % | 1.40 % | 5.00 |
| Alkem Laboratories Ltd | 63,539 Cr. | 5,292 | 5,934/5,051 | 28.0 | 1,156 | 1.00 % | 21.2 % | 18.9 % | 2.00 |
| Glenmark Life Sciences Ltd | 64,624 Cr. | 2,295 | 2,538/1,793 | 20.7 | 372 | 0.22 % | 39.8 % | 23.6 % | 1.00 |
| Glenmark Pharmaceuticals Ltd | 65,605 Cr. | 2,311 | 2,538/1,793 | 21.0 | 372 | 0.22 % | 39.8 % | 23.6 % | 1.00 |
| Lupin Ltd | 92,844 Cr. | 2,029 | 2,530/1,900 | 15.6 | 491 | 0.89 % | 29.9 % | 28.7 % | 2.00 |
| Aurobindo Pharma Ltd | 97,686 Cr. | 1,693 | 1,740/1,066 | 25.8 | 652 | 0.24 % | 12.9 % | 10.1 % | 1.00 |
| Dr Reddys Laboratories Ltd | 1,00,412 Cr. | 1,208 | 1,415/1,080 | 31.2 | 454 | 0.66 % | 13.0 % | 11.2 % | 1.00 |
| Mankind Pharma Ltd | 1,03,222 Cr. | 2,500 | 2,642/1,910 | 45.6 | 397 | 0.04 % | 13.7 % | 13.8 % | 1.00 |
| Cipla Ltd | 1,08,393 Cr. | 1,340 | 1,673/1,166 | 30.3 | 426 | 0.97 % | 15.5 % | 11.6 % | 2.00 |
| Laurus Labs Ltd | 1,11,181 Cr. | 2,050 | 2,055/843 | 127 | 97.3 | 0.10 % | 16.0 % | 15.2 % | 2.00 |
| Torrent Pharmaceuticals Ltd | 1,82,155 Cr. | 4,772 | 5,250/3,480 | 81.6 | 248 | 0.80 % | 15.2 % | 27.4 % | 5.00 |
| Industry Average | 17,635.87 Cr | 1,251.07 | 54.95 | 211.24 | 0.39% | 26.16% | 16.59% | 6.06 |
How to use this peer comparison
Start with similar company sizes, then compare P/E with ROCE and ROE. A lower P/E alone does not establish better value. Negative earnings, unusual items, debt and different reporting dates can make ratios unsuitable for direct comparison.
The company list is ordered by market-cap proximity to Astrazeneca Pharma India Ltd, with P/E as a secondary comparison. The industry-average row uses available stored values across the industry, which can include companies beyond the rows shown. Missing values are not zero.
Open each company report for financial statements and its cited sources. Industry classifications indicate a research peer group, not a verified list of direct commercial competitors.
Read the full Astrazeneca Pharma India Ltd analysis · Explore all Pharmaceuticals stocks